Keywords: strong, early, data, immufact, imp321, breast, cancer

Strong early data for ImmuFact IMP321 in breast cancer

Article | 03 December 2007

Print This

Orsay, France-based Immutep SA reported positive interim results from a Phase I/II study of its lead product, ImmuFact IMP321 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in